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a b s t r a c t
TLR2 agonists arewell known for inducingNF-kB activation and inﬂammation,while estrogen receptor-alpha
(ER-α) is a regulator of estrogen-mediated anti-inﬂammatory responses. In the present work, we determined
the role of ER-α and phosphorylated ER-α in TLR2 agonist-induced MCP1 production in mesangial cells. We
found that TLR2 agonists induced nuclear localization of phospho-ER-α (serine 118), and estrogen and TLR2
agonists both inducedphosphorylationof ER-α at the serine118and104/106positions. IncubationofMRL/lpr
mesangial cellswith estrogenwas found to attenuate TLR2 agonist-mediatedMCP1 production. To determine
the mode of action of ER-α/pER-α (serine-118), we used the ER-α inhibitor MPP and transfected mesangial
cells with ER-α siRNA. ER-α inhibition was found to decrease MCP1 production in mesangial cells. Thus,
ER-α/pER-α is an intermediate regulator for both TLR2-mediatedMCP1 production during inﬂammation and
estrogen-mediated anti-inﬂammatory signals in mesangial cells.
c© 2012 Elsevier B.V.
1. Introduction
A wide range of endogenous agents and subclinical infections
in susceptible hosts induce mesangial cell activation. These acti-
vated mesangial cells play an important role in kidney inﬂamma-
tion and generate reactive oxygen species, reactive nitrogen species,
nitric oxide, inﬂammatory cytokines such as TNF-alpha and IL1,
chemokines, prostaglandins, and matrix metalloproteinases [1,2].
Over time, chronic inﬂammation predisposes localized tissue dam-
age to autoimmune nephritis.
Glomerulonephritis is an end-organ manifestation of autoim-
mune systemic lupus erythematosus. Diffuse proliferative (DPGN)
and membranous glomerulonephritis (MGN) are found during pro-
gression of the disease [3,4]. Investigations fromdifferent laboratories
[5,6], including our own group (Dasgupta et al., unpublished obser-
vations), have indicated that inﬁltration of peripheral immune cells
such as neutrophils, T cells, and monocytes/macrophages in the kid-
ney is associated with inﬂammation and progression of the disease.
The expression of chemokines such as monocyte chemoattractant
protein-1 (MCP1 or CCL2) has been reported in lupus nephritis pa-
tients [6,7]. The chemokineMCP1 and expression of its receptor CCR2
Abbreviations: MCP1, monocyte chemoattractant protein-1; TLR2, toll-like
receptor-2; ER-&, estrogen receptor-alpha
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in humanmesangial cellswere found to induce the intercellular adhe-
sion molecule integrin ICAM-1, which led to monocyte adhesion [8].
Thus, endogenous production of MCP1 is a parameter for tissue in-
ﬁltration and inﬂammatory responses in kidney. Recently, investiga-
tions from different laboratories [911] have suggested the diagnostic
importance of MCP1 in the urine of lupus nephritis patients.
In the murine model of SLE (NZB/W), an increase in MCP1 ex-
pressionwas foundwith in vitro TLR4 ligand lipopolysaccharide (LPS)
treatment in cell culture [12]. LPS is a stimulator of robust inﬂamma-
tory responses and induces activation of monocytes/macrophages
and mesangial cells via a wide range of transcription factors and reg-
ulatory proteins including NF-kB and AP1 [13]. However, there is a
critical role for TLR2 in the response to endogenous and environmen-
tal factors as well. Thus, a mechanism for the induction of inﬂamma-
tory responses via the activation of transcriptional regulators is still
not clear.
Patole et al. [14] and Pawar et al. [15] demonstrated the expression
of several Toll-like receptors (TLR 1–9) and interleukin-6 production
in the kidney tissues of MRL-Fas (lpr) mice with immune complex
glomerulonephritis. Lichtnekert et al. [16] suggested that mesangial
cell activation is due to the activation of TLR2/MyD88 signals rather
than TLR3/Trif signal pathway by surrounding dying cells. These ob-
servations indicated that extracellular TLR2-mediated inﬂammatory
signals in mesangial cells play a major role in lupus nephritis.
The mode of action of ER-α in the onset of female-predominant
autoimmune responses is still not known. Several recent reports sug-
gested the adverse effect of estrogen receptor-alpha (ER-α) in lupus
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Fig. 1. TLR2 agonist lipoteichoic acid induced phosphorylation of ER-α at Serine
118. (A) The MRL/lpr mesangial cells in DMEM/F12 medium were incubated in pres-
ence of lipoteichoic acid (LTA). The cells were immunolabelled with ER-α antibody
(host rabbit) and FITC tagged anti-rabbit IgG as secondary antibody. The ﬂuorescent in-
tensity was determined under a confocal microscope. (B) The MRL/lpr mesangial cells
were stimulatedwith LTA in a time dependentmanner. The cells were immunolabelled
with pER-α (Ser118) antibody (host goat) and FITC-tagged anti-goat IgG as secondary
antibody. The ﬂuorescent intensity was determined under a confocal microscope.
patients and in murine models. Lupus is found to exacerbate pre-
dominantly in females (female to male 9:1) during a period between
puberty and menopause [1719]. Svenson et al. [20] and Bynote et
al. [19] suggested that inhibition of ER-α attenuated disease man-
ifestations in lupus-prone NZM 2410 mice. Recently, Cunningham
et al. [21] demonstrated the beneﬁcial role of ER-α knockout in the
prevention of lupus nephritis in a mice model. Several investigators
have also suggested a role for estrogen and selective estrogen recep-
tormodulators (SERMs) in the prevention ofmesangial cell activation
during progressive renal diseases [2226]. The anti-inﬂammatory roles
of estrogen and estrogen receptors are well-evidenced in experimen-
tal autoimmune encephalomyelitis (EAE), a model for demyelinating
autoimmune disease multiple sclerosis (MS) [27,28].
The objective of the present study was to determine role of ER-α/
phosphorylated ER-α (pER-α) and estrogen in TLR2 agonist-induced
MCP1 production in mesangial cells as a consequence of kidney in-
ﬂammation. We found that estrogen and TLR2 agonists, either alone
or in combination, had the ability to phosphorylate ER-α in mesan-
gial cells. However, TLR2 agonists but not estrogen had the ability
to increase MCP1 production in mesangial cells. Furthermore, inhi-
bition of ER-α decreased TLR2 agonist-induced MCP1 production in
kidney mesangial cells. We also found that estrogen inhibits TLR2
ligand-induced MCP1 production.
Thus, ourﬁndings suggest that ER-α/pER-α (Serine118) is an inter-
mediate regulator of both TLR2-mediated inﬂammatory signals and
estrogen-mediated anti-inﬂammatory responses in kidneymesangial
cells.
2. Materials and methods
2.1. Reagents
Toll-like receptor 2 ligands Pam3CsK4 (Pam) and lipoteichoic acid
(LTA) were purchased from Invivogen (USA). Estrogenwas purchased
from Sigma Chemical Co. (USA). The ER-α inhibitor MPP was pur-
chased from Tocris Bioscience (USA). DMEM/F12, endotoxin free
(charcoal stripped) fetal bovine serum, trypsin-EDTA, l-glutamine,
antibiotics (penicillin–streptomycin solution), and collagenase (type
IV) were purchased from Invitrogen (USA).
2.2. Animals
Female MRL/lpr (4–6 weeks old) and C57BL/6 mice (4–6 weeks
old) were obtained from Jackson Laboratory (Bar Harbor, ME). MRL/
lpr mice are spontaneously susceptible and are a well-known animal
model for lupus. C57BL/6mice are not susceptible to lupus and do not
develop any spontaneous lupus-like immune responses throughout
their life. For experiments, we isolated kidney mesangial cells from
both MRL/lpr and C57BL/6 mice. All age- and sex-matched MRL/lpr
and C57BL/6 mice were normal and healthy. The mice were main-
tained in a pathogen-free institutional animal facility following the
guidance of the local ethical committee. All mice were fed nutrition-
ally balanced standard food chow and water ad libitum.
2.3. Isolation of mouse kidney mesangial cells
Primary mesangial cells were isolated from the kidneys of female
MRL/lpr and C57BL/6 mice following the method described by Mene
[29] with minor modiﬁcations. Brieﬂy, kidneys were dissected, and
cortices were separated out. The cortices were gently teased over
a ﬁne metal screen (50–80 mesh) to remove large debris. Single
cell suspensions were re-suspended in sterile cold PBS (pH 7.2) and
harvested by centrifugation at 1200 rpm at 4 ◦C for 5min. The cell
pellet was incubated with collagenase type IV (2mg/ml) in sterile
PBS at 37 ◦C for 30min. After washing, cells were re-suspended in
DMEM/F12 medium (Phenol red-free) supplemented with 5mM l-
glutamine, 100U/ml penicillin, 100μg/ml streptomycin sulfate and
20% (vol/vol) fetal bovine serum (certiﬁed and charcoal-stripped).
The re-suspended mesangial cells were incubated for 3–5 days in
human ﬁbronectin-coated tissue culture dishes in a 37 ◦C/5% CO2 in-
cubator. The cells in culture appeared as adherent, stellate-shaped
cells under the light microscope (40× magniﬁcation). The purity of
the mesangial cells was determined by immunocytochemistry using
a mouse-speciﬁc antibody for the smooth muscle protein α-actin.
The primarymesangial cells were maintained for 3–5 passages in cell
culture in vitro.
For experimental purposes, the adherent mesangial cells were
trypsinized and harvested at 1200 rpm for 3min at 4 ◦C. Cells were
re-suspended in FBS-free, phenol red-free DMEM/F12 medium. The
number of cells was counted in a Neubauer hemocytometer chamber.
The viability of the cells (>90%) was determined by light microscopy
by the trypan blue exclusion method.
2.4. ELISA
Monocyte chemoattractant protein-1 (MCP1) in mesangial cell
culture supernatants was assayed by sandwich ELISA following the
manufacturers’ instructions (E-Bioscience, USA). Brieﬂy, 5×105 cells
were incubated in wells with different doses of MPP for 8h before
treatment with the TLR2 agonist Pam3CsK4 in vitro. MCP1 was also
assayed in culture supernatants frommesangial cells following incu-
bation with LTA in the presence or absence of estrogen. After 24h
of incubation, cell viability (90%) was determined under a light mi-
croscope by observing the adherent property of the mesangial cells
at the bottom of the tissue culture plate and also by the trypan blue
exclusion method. The supernatants from each well were collected
for the MCP1 assay. The results were expressed as the mean ± SE of
MCP1 concentrations in pg/ml from triplicate experiments.
2.5. Immunoprecipitation and western blot analysis of pER-α
(Serine118) and pER-α (Serine 104/106) from whole cell lysates of
mesangial cells
Primarymesangial cells (1×108 cells) fromC57BL/6 kidneyswere
incubated with TLR2 agonist Pam3CsK4 in the presence or absence of
estrogen (17-ß-estradiol) (10nM) (Sigma, USA) for 30min in a CO2
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incubator.Mesangial cellswithout any TLR2 agonist or estrogen treat-
ment were used as the control for the experiment. After incubation,
supernatants were discarded, and cells in the wells were harvested
in RIPA cell lysis buffer (Tris-buffer saline, 1% NP-40, 0.5% deoxy-
cholate, 0.1% SDS, protease inhibitor cocktail 10μl/ml). The whole
cell lysates (20μg protein) were incubated with Sepharose G beads
taggedwith ER-α antibody (5μg/reaction) (host: rabbit, 2–185 amino
acid sequence of human ER-α) (SantaCruz Biotechnology, USA) at 4 ◦C
overnight in a rocker. The sample mixtures were then spun down at
10,000 rpm at 4 ◦C, washed with Tris buffer (pH 7.2), and processed
for SDS gel electrophoresis. The protein sampleswere prepared in SDS
PAGE sample buffer andboiled in awater bath for 5min. The immuno-
precipitated protein sampleswere then run under gel electrophoresis
(75 volt, 25 ◦C), and the separated proteins in SDS gels were trans-
ferred onto PVDF membranes. Western blot analysis was performed
using primary antibodies for phospho-ER-α (Serine 118) (host:goat)
andpER-α (Serine 104/106) (host:goat) (1:1000dil). The immunopre-
cipitated proteins were detected as a band in an infrared scanner us-
ing a secondary donkey anti-goat IgG-IR 680 antibody (Licor, Odessey,
USA) (1:5000 dil) for pER-α (Serine 118 and Serine 104/106).
The presence of ER-α was detected in the immunoprecipitated
samples with donkey anti-rabbit IgG-IR 800 (1:5000 dil). Digital pic-
tures of the immunoblotswere analyzedby the software incorporated
in the computer that was attached to the scanner (Licor Odessey,
USA).
Western blot analysis was also performed to detect pER-α (Serine
118) in nuclear extracts of TLR2 agonist LTA-treated mesangial cells
in the presence or absence of different doses of the ER-α inhibitor
MPP. Cells (5×106) were pre-incubated with MPP for 8h and then
with the TLR2 ligand LTA. Mesangial cells treated with MPP only but
not with LTA and cells treated with LTA only but not with MPP were
used as controls for the experiment. Nuclear extracts were prepared
30min after in vitro treatment following instructions provided by
the manufacturer (Millipore, USA). Western blot analysis of nuclear
extracts was performed using a primary antibody for pER-α (Serine
118) (1:1000 dil) (host:goat) and a secondary donkey anti-goat IgG-IR
680 antibody (1:5000 dil). The protein band for pER-α (Serine 118)
was detected in an infrared scanner (Licor, Odessey, USA).
In a separate set of experiments, whole cell lysateswere separated
by SDS gel electrophoresis for western blot analysis using a primary
antibody for β-actin (host rabbit) and a secondary anti-rabbit IgG-IR-
800 antibody (1:5000) to detect the constitutively expressed protein
control for the experiment (Fig. 2C).
2.6. Immunocytochemistry
Mesangial cells (1×103 cells per well of a sterile tissue culture
slide) were re-suspended in DMEM/F12 medium (Phenol red-free).
The cells were incubated with TLR2 agonist lipoteichoic acid (10ng/
ml) in DMEMmediumunder FBS and Phenol red-free DMEMmedium
atdifferent times as indicated in theﬁgures. Then, the culturemedium
was aspirated out, andmesangial cells in the wells were ﬁxed follow-
ing a routine procedure for immunocytochemistry. The ﬁxed mesan-
gial cells were incubated with a ER-α antibody (host:rabbit) (Santa
Cruz, USA) (1:200 dil. in TBS, pH 7.2) and a pER-α (host: goat) an-
tibody (Santa Cruz, USA) (1:200 dil.) for 1h at room temperature.
After washing with TBS and 0.05% Tween 20, mesangial cells were
stainedwith a secondary donkey anti-rabbit IgG-FITC antibody (1:400
dil. in TBS) and a donkey anti-goat IgG-FITC antibody for an hour at
room temperature. Slides were mounted using Gold antifade mount-
ing medium (Invitrogen, USA). Cells incubated only with secondary
antibodies were used as background controls or base level correc-
tion for this set of experiments (not shown in ﬁgures). Immunoﬂu-
orescence signals over the background controls were considered for
observation. The ﬂuorescent intensity of immunolabelled cells was
observed under a confocal microscope (Leica). Digital pictures of the
Fig. 2. Effect of estrogen and TLR2 agonist Pam3CsK4 on phosphorylation of ER-α
in mesangial cells. The mesangial cells in DMEM/ F12 medium were incubated with
estrogen, Pam3CsK4 and combination of both for a period of 30min in a CO2 incuba-
tor. The mesangial cells, received dimethyl sulfoxide (DMSO) as vehicle for estrogen
and DMEM/F12 medium only as vehicle for Pam3CsK4, were used as control for this
experiment. Following incubation, supernatants were discarded and mesangial cells
were harvested in RIPA buffer for preparation of whole cell lysates. The ER-α was im-
munoprecipitated out using ER-α antibody (host rabbit, 2–185 amino acid of hER-α) as
described in Materials and methods. The western blot analysis of these immunopre-
cipitated samples were performed using (A) phospho ER-α (Ser 118) (host goat) and
(B) phospho ER-α (Ser104/ 106) (host goat). The secondary antibody donkey anti-goat
IgG-IR 680 was used to determine pER-α. The immunoprecipitated ER-α in samples
was detected by rabbit ER-α antibody and donkey anti-rabbit IgG taggedwith IR 800 as
secondary antibody. (C) Western blot analysis of the whole cell lysates frommesangial
cells following treatment with different doses of TLR2 agonist in vitro. The constitutive
protein β- actin was demonstrated in the cell lysates.
Fig. 3. Effect of ER-α inhibitor MPP on phosphorylated ER-α (Ser 118) in nuclear
extract of LTA treated mesangial cells. The mesangial cells were incubated with
different doses of MPP in presence of LTA (10ng/ ml) as described in Materials and
methods. After 30minutes of incubationwith LTA, cells were harvested for preparation
of nuclear extracts. The western blot analysis of nuclear extracts determined presence
of pER-α (Ser 118). The lanes contained pER-α (Ser118) in the nuclear extracts from
mesangial cells incubated with only LTA, and LTA with different doses of MPP. The
nuclear extracts isolated frommesangial cells treated with MPP only and TLR2 agonist
only were used as control. The “ ± ” and “ – “ signs in the ﬁgure indicated presence and
absence of either TLR2 agonist or estrogen as pERa (Ser 1118) activator in mesangial
cells. The molecular weights were shown in the ﬁgure (kDa).
immunolabelled cells were analyzed by software on the computer
attached to the microscope.
2.7. siRNA transfection
Transient transfection of primary mesangial cells with estro-
gen receptor-alpha silencer RNA (siER-α) (Santa Cruz, USA) was
performed using the Siport transfection reagent (Ambion, USA).
Brieﬂy, mesangial cells were collected following trypsinization using
Trypsin–EDTA solution for 20min at 37 ◦C. After subsequent washes,
cells were re-suspended in DMEM/F12 medium and harvested at
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Fig. 4. ER-α siRNA transfection in mesangial cells. Mesangial cells were transfected
with different doses of ER-α siRNA and scrambled siRNA (control). The relative ex-
pression of ER-α mRNAwas determined by realtime PCR. The efﬁciency of transfection
was determined by difference between ER-α mRNA expression of scrambled siRNA
transfected control and ER-α siRNA transfected cells. Results were presented as mean
± SE of triplicate experiments.
1200 rpm for 3min at 4 ◦C. Mesangial cells (5×104 cells per well)
were re-suspended in FBS-free DMEM/F12 medium in a 12-well tis-
sue culture plate and were transiently transfected with ER-α siRNA
(0.5μM) or with scrambled siRNA (used as control siRNA) in Siport
NeoFx transfection reagent (Ambion, USA). After 4 h of incubation at
37 ◦C/5% CO2 atmosphere, an equal volume of DMEM/F12 medium
(20% FBS) was added to each well, keeping the ﬁnal FBS concen-
tration at 10% (v/v) per well. Following 16h of further incubation,
siRNA-transfected mesangial cells were used for experimental pur-
poses. The viability of the transfected mesangial cells (90%) in each
well of tissue culture plate was observed by light microscope.
The efﬁciency of ER-α siRNA transfection (0.05–0.5μM of
lyophilized siRNA) was determined by real time RT-PCR from cDNA
samples isolated from mouse primary mesangial cells. The trans-
fection efﬁciency (40%) was determined by comparing the rel-
ative mRNA expression of ER-α in scrambled and ER-α siRNA-
transfected mesangial cells. For this purpose, we used primers for
mouse ER-α: forward 5′-ATGAAAGGCGGCATACGGAAAG-3′ , reverse
5′-CACCCATTTCATTTCGGCCTTC-3′ (Fig. 4).
2.8. Real time qRT-PCR
Primary mesangial cells were incubated with Pam3CsK4 for a pe-
riod of 6h. Total RNA was isolated from mesangial cells using TRIzol
(Invitrogen, USA) and the Qiagen RNA isolation kit (Qiagen, USA).
The cDNA samples were prepared by following the instructions of
the Superarray cDNA preparation kit (Superarray, USA). Ampliﬁca-
tion of cDNA was performed by quantitative real time PCR (qRT-
PCR) (MyIQ BioRad, USA) using RT2 real-time SYBR Green ﬂuores-
cein PCR mastermix from Superarray (USA). The real time primers
used were mouse MCP1: forward 5′-CTTCTGGGCCTGCTGTTCAC-
3′, reverse 5′-GGGATCATCTTGCTGGTGAA-3′; and mouse β-
actin: forward 5′-TCCTCCCTGGAGAAGAGCTA-3′ and reverse 5′-
CCAGACAGCCACTGTGTTGGC-3′. The relative mRNA expression of
MCP1 was determined by comparison with the expression of the
housekeeping gene mouse β-actin as well as with corresponding un-
stimulated controls (control value set as 1). We found similar expres-
sion patterns with 18S RNA primers for real time PCR (SABiosciences,
Qiagen, USA) as for constitutive β-actin. The results were expressed
as the mean ± SE of three different experiments.
2.9. Statistical analysis
The student’s t-test was used to determine statistical signiﬁcance
of the results comparedwith corresponding controls. The signiﬁcance
level (p <0.05) was determined by calculated p-values.
3. Results
3.1. TLR2 agonists activate ER-α in MRL/lpr mesangial cells
Phosphorylation at Serine104/106 and Serine 118 on the ER-α
protein determines ER-α activity [30,31] and is required for estrogen-
mediated gene expression. However, a relationship between ER-α
activation and TLR2 agonist-induced MCP1 production in activated
mesangial cells is not yet well determined. We wanted to determine
the effect of ER-α and phosphorylated ER-α (Serine118) on TLR2-
mediated induction of MCP1 production in mesangial cells.
The 4–6 weeks old female MRL/lpr and C57BL/6 mice utilized
were phenotypically normal and healthy. These mice were used to
isolate mesangial cells. The results presented in Fig. 1 demonstrated
that the TLR2 agonist lipoteichoic acid (LTA) induced ER-α activation
(Fig. 1A). The ﬂuorescent intensity of MRL/lpr mesangial cells follow-
ing treatment with LTA in vitro was found to increase compared to
the untreated control. These observations (Fig. 1A) also indicated an
overall activation of ER-α in mesangial cells.
The effect of LTA treatment on localization of phosphorylated ER-
α [pER-α (Serine 118)] in MRL/lpr mesangial cells was determined
in vitro. The results presented in Fig. 1B demonstrated the localiza-
tion of pER-α (Serine118) in the nuclei of mesangial cells. The time-
dependent observations indicated that the ﬂuorescent intensity of
phosphorylated ER-α in MRL/lpr mesangial cells was optimal after
20minof LTA stimulation andgradually decreasedover a 40-min time
interval following LTA treatment in vitro. At the 0min time point, a
basal level of pER- α (Ser 118) was observed in mesangial cells.
3.2. Effect of estrogen and toll-like receptor 2 agonists on the
phosphorylation of ER-α in mesangial cells
To determine the effect of TLR2 agonists and estrogen on the
phosphorylation of ER-α, we incubated C57BL/6mesangial cells with
estrogen alone (10nM) and in combination with the TLR2 agonist
Pam3CsK4 (10ng/ml). The immunoprecipitation of ER-α and west-
ern blot analysis for pER-α (Serine 118) and pER-α (Serine 104/106)
in whole cell lysates of mesangial cells demonstrated that estrogen
and the TLR2 agonist Pam3CsK4 both had the ability to activate ER-α
through phosphorylation at the Serine 118 and also the Serine 104/
106 position compared to the control. Treatment with the combi-
nation of estrogen and Pam3CsK4 was also found to induce phos-
phorylation of ER-α in mesangial cells (Fig. 2A and B). The results
in the ﬁgures demonstrated that estrogen and Pam3 CsK4 induced a
marginal increase in ER-α/pER-α. However, there was no synergistic
effect of estrogen and Pam on phosphorylation of ER-α at Serine 118
(Fig. 2A) and at Serine 104/106 position (Fig. 2B) in mesangial cells.
3.3. Inhibition of ER-α by MPP and transfection with ER-α siRNA
inhibits MCP1 production in TLR2 agonist-treated mesangial cells
Next, we wanted to determine whether inhibition of ER-α has
any effect on the nuclear localization of pER-α (Serine 118) in TLR2
ligand-induced MCP1 production in C57BL/6 mesangial cells.
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Nuclear extracts were prepared from mesangial cells following
treatment with the ER-α inhibitor MPP in the presence of the TLR2
ligand lipoteichoic acid (LTA) in vitro. Western blot analysis was per-
formed using these nuclear extracts to determine pER-α (Serine118).
The results presented in Fig. 3 demonstrated that nuclear extracts
of MRL/lpr mesangial cells treated only with MPP (1μM) and not
with LTA had a minimum level of pER-α (Ser 118), while the nu-
clear extracts of mesangial cells treated only with LTA demonstrated
an increased level of pER-α (Serine 118) at 66 kDa. The treatment of
LTA-stimulated mesangial cells with MPP at 1μM and 2.5μM was
found to attenuate pER-α (Serine 118) at 66 kDa in nuclear extracts.
There was no detectable change in band intensity for the bands found
at 100kDa and 45kDa in the nuclear extracts prepared from LTA-
treated mesangial cells incubated with or without MPP treatment.
To determine the effect of ER-α inhibition on TLR2 ligand-induced
MCP1 production, we attempted to knock down ER-α in mesangial
cells by transfection with ER-α siRNA in vitro. The transfection ef-
ﬁciency of different doses of ER-α siRNA and scrambled siRNA was
determined in C57BL/6mesangial cells. Real time PCRwas performed
using ER-α primers as described in the Materials and methods. The
results presented in Fig. 4 demonstrated that ER-α siRNA transfection
reduced ER-α mRNA expression by 40% compared to control scram-
bled siRNA-transfected mesangial cells. The siRNA range of 0.05–
0.5μM was found to efﬁciently reduce ER-α mRNA expression. We
used the 0.5μM dose of siRNA for further experiments.
The role of ER-α in TLR2 agonist-induced MCP1 production was
determined by using the ER-α inhibitor MPP at different doses in
the presence and absence of TLR2 agonist in vitro. The cells were
incubatedwithMPP8hbefore LTA treatment.After24h, supernatants
were collected to assay MCP1 production. The results presented in
Fig. 5A demonstrated that MPP at the doses of 1.6–3.2μM has the
ability to decrease MCP1 production signiﬁcantly (p <0.005) in TLR2
agonist Pam3CsK4-treated mesangial cells compared to cells treated
with Pam3CsK4 without MPP. The untreated cell supernatants were
used as the control for MCP1 production.
The ER-α siRNA- and scrambled siRNA-transfectedmesangial cells
were treated in vitro with Pam3CsK4 (10ng/ml) for a period of 24h.
After that, supernatants were collected, and MCP1 production was
estimated by ELISA. The results presented in Fig. 5B demonstrated
that mesangial cells transfected with scrambled siRNA had the abil-
ity to produce MCP1 following incubation with Pam3CsK4 compared
to un-stimulated controls. The ER-α siRNA-transfected mesangial
cells demonstrated signiﬁcantly reduced MCP1 production follow-
ing Pam3CsK4 treatment in vitro compared to control (scrambled)
siRNA-transfected cells (p <0.005). Mesangial cells transfected with
either ER-α siRNA or scrambled siRNA without Pam3CsK4 treatment
were used as controls for MCP1 production.
Next, we determined the relative mRNA expression of MCP1 in
the ER-α siRNA-transfected mesangial cells after incubation with
Pam3CsK4. The mRNA expression of MCP1 in ER-α siRNA-transfected
mesangial cells was found to decrease signiﬁcantly (p <0.005) com-
pared to scrambled siRNA-transfected Pam3CsK4-treated mesangial
cells (Fig. 5C).
3.4. Estrogen inhibits TLR2 agonist LTA-treated MCP1 in MRL/lpr
mesangial cells
Next, we determined the effect of estrogen onMCP1 production in
TLR2 ligand-treatedmesangial cells. For this,mesangial cells (5×105)
were incubated with estrogen (10nM), LTA (10ng/ml) and the com-
bination of estrogen and LTA for 24h. After that, supernatants were
collected to assay for MCP1 using ELISA. The results presented in
Fig. 6 demonstrated that the TLR2 ligand lipoteichoic acid induced
production of MCP1 similar to that observed with Pam3CsK4-treated
mesangial cells in vitro. Treatment with estrogenwas found to inhibit
LTA-inducedMCP1 production inmesangial cells (p<0.05). However,
Fig. 5. Inhibition of ER-α decreased MCP1 production in mesangial cells. (A) The
C57BL/6 mesangial cells in DMEM/F12 medium (without FBS) were incubated with
different doses of MPPwith TLR2 ligand Pam3CsK4 (10ng/ml) for 24h in a CO2 incuba-
tor. The unstimulated cells without anyMPP treatmentwere used as control. After 24h,
the supernatants were collected and presence ofMCP1was assayed by sandwich ELISA
following manufacturer’s instruction. Results were presented as mean ± SE of three
different experiments. The signiﬁcance levels were determined by *p-values in the ﬁg-
ures. The * indicatedMCP1production inPam3CsK4 treatedmesangial cellswithout any
treatment with MPP. The ** indicated MCP1 production in mesangial cells incubated
with Pam3CsK4 and MPP. **p<0.005. (B) The MCP1 production in ER-α siRNA trans-
fected mesangial cells was determined as described in Materials and methods. The
transfected cells were incubated with Pam3CsK4 (10ng/ ml) for 24h. The mesangial
cells transfected with scrambled siRNA was used as positive control for these experi-
ments. The cells, either transfectedwith ER-α siRNA alone or cells without transfection
were used as negative control. The MCP1 production was assayed in the culture super-
natants by using quantitative ELISA following manufacturer’s instruction. The results
were expressed as mean ± SE of triplicate experiments. The **p<0.005. (C) The mRNA
expression of MCP1 was determined by using Real time PCR as described in Materials
and methods. The ER-α siRNA transfected mesangial cells were treated in vitro with
TLR2 ligand Pam3CsK4 (10ng/ ml) for 6h. The cells either in DMEM/F12 medium alone
or transfected with ER-α siRNA without any treatment were used as control. After 6 h,
cells were harvested in Trizol and Qiagen RNA isolation kit. The cDNA samples were
prepared and processed for real time PCR using MCP1 primers. The results presented
as mean ± SE of relative mRNA expression for MCP1 in mesangial cells compared
with corresponding β-actin as constitutive expression and with unstimulated cell only
control.
treatment with estrogen alone with or without ER-α siRNA transfec-
tion had no effect on MCP1 production. Additionally, treatment of
ER-α siRNA-transfected mesangial cells with estrogen had no effect
on MCP1 production. The untreated mesangial cells and scrambled
siRNA transfected cells were used as controls for MCP1 production in
vitro.
4. Discussion
Mesangial cells are known to play a vital role in kidney inﬂam-
mation [1]. In systematic autoimmune lupus, glomerulonephritis is a
predominant and fatal end-organ disease. Though the mechanism of
glomerular inﬂammation is not clear, it is known that auto-antibody
production, complement cascadeactivationand formationof immune
complexes have an impact on inﬂammation and the progression of
disease in susceptible hosts [32]. The importance of extracellular in-
nate immune receptor TLR2 in glomerulonephritis depends largely
on the nature of its interaction with endogenously derived ligands
and environmental factors via a mechanism that is not yet clear. Our
observations suggested that, at an early stage of life, TLR2 agonists
play an important role in mesangial cell activation and inﬂammation.
We found thatmesangial cells from 4 to 6week old lupus-susceptible
MRL/lpr mice and from lupus-unrelated C57BL/6 mice respond sim-
ilarly to TLR2 agonists to produce MCP1 in vitro. The overall immune
responses in lupus-susceptible MRL/lpr mice start at 15–16 weeks
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Fig. 6. Estrogen treatment in vitro down regulate MCP1 production in LTA treated
mesangial cells. The MRL/lpr mesangial cells in DMEM/F12 medium were incubated
in vitro with TLR2 ligand LTA (10ng/ ml); estrogen (solubilised in DMSO; 10nM); and
combination of both LTA and estrogen for a period of 24h. The mesangial cells trans-
fected with ER-α siRNA was also treated with estrogen (10nM). The cells without any
treatment, or transfected with either ER-α siRNA or control (scrambled) siRNA only
without any LTA and estrogen treatment were used as control in this experiment. The
MCP1 production in 24h culture supernatants following in vitro treatment was assayed
by using sandwiched ELISA as per manufacturer’s instruction. The results presented as
mean ± SE of three different experiments. The level of signiﬁcance was determined
by comparing MCP1 production in LTA treated cells versus LTA treated cells incubated
with estrogen; **p<0.05. The effect of estrogen in MCP1 production was compared in
ER-α siRNA transfected mesangial cells and was also shown in the ﬁgure.
and attain a peak value at 20–22weeks of age. TLR2 agonist(s) exacer-
bate the immune responses, includingB cell activation, in these 20–22
week old mice ( Dasgupta S., Molano I. Speciﬁc antigenic recognition
shifts a balance from tolerance to effector immune responses in lupus
cerebritis. J. Immunol. (Abstract) 2012 188: 173.34). . Thus, antigen-
speciﬁc activation of TLR2 plays an important role in inﬂammatory
immune responses in mesangial cells. The inﬁltration of neutrophils,
CD11b and CD3ε can be correlated with increased MCP1 production
and the increase in TLR2 expression in mesangial cells (Dasgupta et
al., unpublished observations). These inﬁltrating immune cells take
part in localized inﬂammatory responses and cause tissue damage
during progression of disease.
Our observations in primary mesangial cells suggested that es-
trogen receptor-alpha (ER-α) takes part in TLR2 agonist-mediated
MCP1 production. We found that TLR2 ligands and estrogen, either
alone or in combination, induced phosphorylation of ER-α at Serine
118 and Serine 104/106 in mesangial cells. The phosphorylation of
estrogen receptor-alpha at Serine 118 and Serine104/106 residues
causes activation of ER-α [30,31,33]. However, the consequences for
such phosphorylation and thus an altered protein conformation of
pER-α are still not known in a physiological context and in the onset
of female-predominant autoimmune disease. The phosphorylation–
dephosphorylation process plays a key role not only in receptor ac-
tivation but also in the alteration of its protein structure and confor-
mation, which is an essential part of the receptor–ligand interaction.
Although TLR2 agonists and estrogen both have the ability to phos-
phorylate ER-α at Serine 118 and Serine 104/106, our observations
didnot demonstrate any remarkable synergistic effect for the agonists
and estrogen on ER-α phosphorylation in mesangial cells. The ﬁnd-
ings indicated a saturation level of serine amino acid phosphorylation
at the 118 and 104/106 sites of the ER-α protein molecule. Recently,
Colasanti et al. [34] demonstrated the presence of an autoantibody
against ER-α in SLE patients. Therefore, structure and conformation
of ER-α/pER-α protein molecule and the nature of its interactions
with different TLR2 ligands and estrogen have profound importance
in female gender-predominant autoimmune lupus.
Our observations also suggested that the ER-α inhibitor MPP re-
duced pER-α (Serine 118) at 66 kDa in the nuclear extracts ofMRL/lpr
kidney mesangial cells. The band intensities at 100 kDa and 45kDa
were altered with increasing MPP doses. Additionally, immunopre-
cipitation of ER-α and western blot analysis of pER-α (Serine 118)
suggested that ER-α/pER-α was a major band at 66 kDa. Similar ob-
servations were also found for pER-α (Serine 104/106) in mesangial
cells. Furthermore,we found that exogenous estrogen inhibited TLR2-
mediated MCP1 production, although estrogen alone barely has any
effect on the production of the inﬂammatory chemokine MCP1 in
mesangial cells. Thus, we suggest a dual responsive role for ER-α to-
ward TLR2 signaling and estrogen-mediated signaling in mesangial
cells.
Our observations, alongwithﬁndings fromother laboratories, sug-
gested that attenuation of mesangial cell activation is an important
step for the management of autoimmune nephritis. Autoimmune SLE
is found in female patients during childbearing years, when estro-
gen plays a vital physiological role. However, our observations and
also the ﬁndings from other laboratories indicated the beneﬁcial im-
portance of estrogen in the prevention of mesangial cell activation.
Therefore, endogenously synthesized estrogen in female SLE patients
is not sufﬁcient to combat the severity of disease progression. There
is a possibility that autoantibodies, complement and immune com-
plexes activate TLR2-mediated inﬂammatory signaling, which sup-
presses estrogen-mediated anti-inﬂammatory responses in the kid-
neys. Thus, the inhibition of TLR2-mediated inﬂammatory signals and
a decrease in MCP1 expression in kidney mesangial cells are impor-
tant for the attenuation of inﬂammation in several ways. The at-
tenuation of estrogen-independent ER-α activation signaling as well
as the selective use of estrogenic compounds and estrogen-like ER-
α modiﬁers (SERMs) are found possible targets for therapy in kid-
ney inﬂammation. Favoring these possibilities, we found that ER-α/
pER-α (Serine 118) is an intermediate common regulator for both
estrogen-mediated anti-inﬂammatory pathways and TLR2-mediated
inﬂammation-induced NF-kB activation in mesangial cells in kidney
glomeruli. The anti-inﬂammatory role of estrogen has been demon-
strated in murine models of renal disease. Estradiol was found to re-
verse TGF-β mediated renal injury in Alb/TGF-beta1 transgenic mice
and p53 knockout mice [35,36]. On the other hand, Potier et al. [37]
indicated that there were limitations of estrogen in the treatment
of genetically susceptible glomerulosclerosis in mice. Physiological
doses of estrogen decreased type I and type II collagen accumulation
inmesangial cells isolated fromglomerulosclerosis-resistantmice but
not in cells from susceptible mice.
We found double bands at 66 kDa, and 100kDa in the immunoblot
analysis that were recognized as pER-α (Serine 118) by a polyclonal
antibody in the nuclear extracts of MRL mesangial cells (Fig. 3). The
reason for this is not clear. However, the possibility of degradation
or the presence of a modiﬁed and isotypic form of ER-α in mesangial
cells cannot be discounted during treatment with different stimula-
tors, including ER-αmodiﬁers. Several reports suggested that nuclear
as well as membrane-bound ER-α is found in different cell types such
as epithelial cells and endothelial cells [30,31,38,39]. The bound ER-
α is intimately involved in intracellular G-protein coupled signaling
through MAPK and the Akt-PI3K pathways. Estrogenic signal trans-
duction induces modulation of estrogen-responsive genes by binding
at the ERE sequence element in DNA. Our ﬁndings suggested that
MCP1 production in mesangial cells is regulated, at least in part, by
ER-α/pER-α. A decrease in the relative band intensity of pER-α (Ser-
ine 118) at 66 kDa in the presence of the ER-α inhibitorMPP indicated
that the 66kDa ER-α/pER-α (Serine 118) is amajor fraction that plays
a modulator role in the nucleus during MCP1 expression in mesan-
gial cells. Our ﬁndings demonstrated the ability of TLR2 agonists to
202 S. Dasgupta , Jackie Eudaly / Results in Immunology 2 (2012) 196–203
induce nuclear localization of pER-α in mesangial cells, which sug-
gested not only a role for TLR2 but also indicated the importance of
nuclear pER-α inMCP1 production andmesangial cell activation.MPP
is a highly selective antagonist for ER-α [40]. It is >200 fold selective
for ER-α over ER-β. We used this selective antagonist to determine
the importance of ER-α in TLR2 agonist-induced MCP1 production in
kidney mesangial cells.
Different investigators [19,20,41] have demonstrated a detrimen-
tal role for ER-α in the progression of lupus nephritis in the suscep-
tible NZM 2410 spontaneous mouse model. We found that inhibition
of ER-α activation signiﬁcantly (p≤0.05) decreased MCP1 production
in TLR2 agonist-activated MRL/lpr mesangial cells. In systemic lupus,
estrogen and its receptors, ER-α and ER-β, are reported to exacerbate
ﬂares and disease in a particular strain ofmice, e.g., Balb/c andR4A-Tg
mice on a Balb/c background. These mice alter the B cell maturation
and selection process during autoimmune manifestations [42]. Re-
cently, Dai et al. [43] suggested that estrogen inhibits iNOS expression
and prevents NF-kB activation through a decrease in the DNA binding
activity of STAT-1 in spleen cells of C57BL/6 mice. Earlier, Tetsuka
et al. suggested diverse signal regulations for NF-kB activation. The
blockade of upstream tyrosine kinase did not block IL-1ß-inducedNF-
kB activation in mesangial cells [44]. In this context, our observations
suggested that extracellular membrane-bound TLR2-mediated signal
pathways induced downstream activation of ER-α through phospho-
rylation, which is a mechanism of mesangial cell activation during
autoimmune lupus nephritis.
Different laboratories [45,46] have also suggested the diverse na-
ture of ER-α as a transcriptional regulator as well as a membrane-
bound receptor [47,48]. The structure of ER protein molecules and
splice variation generates a wide diversity in the ER mode of action
in different tissues and organs. Recently, it has been demonstrated
that a speciﬁc sequence in the ER-α hinge region is responsible for
its nuclear translocation and tethering ability with an ERE/AP1 DNA
binding domain [49]. In mesangial cells, nuclear pER-α thus has the
ability to diversely affect differential gene expression via interaction
with its DNA binding site as well as with other transcriptional regula-
tors and therefore regulate ligand-mediatedmesangial cell activation.
Selective inhibitors for the activation of mesangial cells are thus one
possible approach to prevent kidney inﬂammation [23].
In autoimmune lupus nephritis, endogenously expressed Toll-
like receptors were found in immune complex glomerulonephritis-
positive MRL/lpr mice [14,15,50]. It has also been found that inﬂam-
matory signaling through MyD88 can cause tissue injury, because
mice deﬁcient in MyD88 have less tissue damage in sterile and non-
infectious situations like encephalomyelitis and kidney transplan-
tation [50]. Thus, the naturally available TLR2 agonist lipoteichoic
acid (LTA) and synthetic agonist Pam3CsK4 both act similarly to in-
duce MCP1 activation in mesangial cells via TLR2/MyD88 signaling
throughER-α. Therefore, the observations inmesangial cells indicated
a mechanism in which ER-α/pER-α (Serine 118) is an intermediate
regulator playing a dual role: (a) TLR2/MyD88-mediated signaling
forMCP1production aswell as (b) transmission of estrogen-mediated
anti-inﬂammatory signals inmesangial cells. Further studieswill pro-
vide the mode of action of ER-α/pER-α (Serine 118) in the regulation
of estrogen-induced anti-inﬂammatory responses and TLR2 signal-
mediated proinﬂammatory gene expression in different tissues dur-
ing autoimmune onset.
4.1. Conclusion
These observations demonstrate an involvement of ER-α/pER-α
(Serine 118) in TLR2 signal-induced MCP1 production. Estrogen has
the ability to attenuate TLR2 agonist-induced MCP1 production in
mesangial cells.
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